A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

This study was comprised of three substudies. The objective of Substudy 1 was to characterize
the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing
clinical remission to identify the induction dose of upadacitinib for further evaluation in
Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of
upadacitinib compared to placebo in inducing clinical remission in participants. The
objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to
placebo in achieving clinical remission in participants who had a response following
induction with upadacitinib.